[Tolerance increase of k-strophantin-alpha through d,l-alpha-tocopherol acetate. Clinical studies in patients with decompensated heart diseases].
D000284:Administration, Oral; D000368:Aged; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000494:pharmacology; D003327:Coronary Disease / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004361:Drug Tolerance / Q000187:drug effects; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D013328:Strophanthins / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D014810:Vitamin E / Q000494:pharmacology* / Q000627:therapeutic use
D002301:Cardiac Glycosides; D004338:Drug Combinations; D013328:Strophanthins; D014810:Vitamin E
Toleranzsteigerung von k-Strophanthin-alpha durch DL-alpha-Tocopherolacetat. Klinische Untersuchungen an dekompensierten Herzkranken.